(The Hill) — The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices. According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products, Novo Nordisk’s Wegovy and Lilly’s Zepbound, for a […]
Related Posts
-
KDDI edges into Vietnam market with VNPT partnership
Japanese telco exports its hyper-personalized digital-only model.
-
Catholic priest who criticized Trump immigration crackdown named bishop
West Virginia’s next Catholic bishop was born in El Salvador and has been critical of…
-
Explosion at a fireworks plant in China kills at least 21 people
Nearly 500 rescuers were deployed to the scene and residents in danger zones were evacuated
-
New Mexico and Meta return to court for bench trial over public nuisance claims
Following a $375 million jury penalty, a judge will now weigh more than 75 proposed…
Leave a Reply